Driver mutation subtypes involve with differentiated immunophenotypes influencing pancreatic cancer outcomes

Area of Science:

• Oncology
• Immunology
• Genomics

Background:

• Pancreatic ductal adenocarcinomas (PAADs) have complex genomic and immune landscapes.
• Understanding the interplay between driver mutations and immune characteristics is crucial for PAAD prognosis.

Purpose of the Study:

• To investigate the relationship between major driver mutation subtypes and immunophenotypes in PAAD.
• To identify genomic features associated with distinct immune microenvironments and patient outcomes.

Main Methods:

• Analysis of RNA expression data to define immune subtypes in PAAD.
• Comparison of immune profiles between different KRAS and TP53 mutation statuses.
• Multiplex immunohistochemistry to characterize tumor microenvironment.

Main Results:

• KRAS G12V / TP53 wild-type (wt) patients exhibited an inflamed immune microenvironment and superior survival post-chemotherapy compared to KRAS G12D / TP53 mutant patients.
• Immune subtype C3 (inflammatory, high Th1/Th2 ratio) was enriched in KRAS non-G12D / TP53 wt patients.
• Immune subtype C2 (IFN-γ dominant, low Th1/Th2 ratio) was more prevalent in KRAS G12D / TP53 mutant patients.

Conclusions:

• The KRAS G12V / TP53 wt genotype is associated with a favorable immune context and better outcomes in PAAD patients receiving adjuvant chemotherapy.
• KRAS G12V / TP53 wt may serve as a predictive biomarker for identifying PAAD patients who benefit from specific immunotherapies or chemotherapies.